{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:02:49Z","timestamp":1773975769203,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["16\/154\/01"],"award-info":[{"award-number":["16\/154\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment Resistant Bipolar Depression (TRBD) is a major contributor to the burden of disease associated with Bipolar Disorder (BD). Treatment options for people experiencing bipolar depression are limited to three interventions listed by National Institute for Health and Care: lamotrigine, quetiapine and olanzapine, of which the latter two are often not well tolerated. The majority of depressed people with BD are therefore prescribed antidepressants despite limited efficacy. This demonstrates an unmet need for additional interventions. Pramipexole has been shown to improve mood symptoms in animal models of depression, in people with Parkinson\u2019s Disease and two proof of principle trials of pramipexole for people with BD who are currently depressed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PAX-BD study, funded by the United Kingdom (UK) National Institute for Health Research, aims to extend previous findings by assessing the efficacy, safety and health economic impact of pramipexole in addition to mood stabilisers for patients with TRBD. A randomised, double-blind, placebo controlled design is conducted in a naturalistic UK National Health Service setting. An internal pilot study to examine feasibility and acceptability of the study design is included. Participants with TRBD are screened from National Health Service secondary care services in up to 40 mental health trusts in the UK, with the aim of recruiting approximately 414 participants into a pre-randomisation phase to achieve a target of 290 randomised participants. Primary safety and efficacy measures are at 12\u2009weeks following randomisation, with follow up of participants to 52\u2009weeks. The primary outcome is depressive symptoms as measured by Quick Inventory for Depressive Symptomatology \u2013 Self Report. Secondary outcomes include changes in anxiety, manic symptoms, tolerability, acceptability, quality of life and cost-effectiveness. Outcome measures are collected remotely using self-report tools implemented online, and observer-rated assessments conducted via telephone. ANCOVA will be used to examine the difference in rating scale scores between treatment arms, and dependent on compliance in completion of weekly self-report measures. A mixed effects linear regression model may also be used to account for repeated measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN72151939. Registered on 28 August 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN72151939\">http:\/\/www.isrctn.com\/ISRCTN72151939<\/jats:ext-link><\/jats:p>\n                <jats:p><jats:bold>Protocol Version:<\/jats:bold> 04-FEB-2021, Version 9.0.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03322-y","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T09:02:56Z","timestamp":1625475776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study)"],"prefix":"10.1186","volume":"21","author":[{"given":"Lumbini","family":"Azim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hindmarch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana","family":"Browne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Clare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndsey","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichola","family":"Duffelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Fouweather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Goudie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timea","family":"Helter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Mawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"McCaffery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R. A.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenn","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Weetman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faye","family":"Wolstenhulme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-1834","authenticated-orcid":false,"given":"R. Hamish","family":"McAllister-Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"issue":"2","key":"3322_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1590\/1516-4446-2012-1693","volume":"37","author":"AS Clemente","year":"2015","unstructured":"Clemente AS, Diniz BS, Nicolato R, Kapczinski FP, Soares JC, Firmo JO, et al. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Rev Bras Psiquiatr. 2015;37(2):155\u201361. https:\/\/doi.org\/10.1590\/1516-4446-2012-1693.","journal-title":"Rev Bras Psiquiatr"},{"issue":"5","key":"3322_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bdi.12296","volume":"17","author":"LV Kessing","year":"2015","unstructured":"Kessing LV, Vradi E, Andersen PK. Life expectancy in bipolar disorder. Bipolar Disord. 2015;17(5):543\u20138. https:\/\/doi.org\/10.1111\/bdi.12296.","journal-title":"Bipolar Disord"},{"issue":"6","key":"3322_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"LL Judd","year":"2002","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530\u20137. https:\/\/doi.org\/10.1001\/archpsyc.59.6.530.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"3322_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","volume":"60","author":"LL Judd","year":"2003","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261\u20139. https:\/\/doi.org\/10.1001\/archpsyc.60.3.261.","journal-title":"Arch Gen Psychiatry"},{"key":"3322_CR5","volume-title":"Bipolar disorder: Assessment and management. NICE","author":"National Institute for Health and Care Excellence","year":"2014","unstructured":"National Institute for Health and Care Excellence. Bipolar disorder: Assessment and management. NICE; 2014."},{"issue":"7","key":"3322_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351\u201360. https:\/\/doi.org\/10.1176\/appi.ajp.162.7.1351.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"3322_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079\u201388. https:\/\/doi.org\/10.1001\/archpsyc.60.11.1079.","journal-title":"Arch Gen Psychiatry"},{"key":"3322_CR8","volume-title":"Prescribing valproate for bipolar disorder. Topic 15a baseline audit report. Royal College of Psychiatrists","author":"Prescribing Observatory for Mental Health","year":"2016","unstructured":"Prescribing Observatory for Mental Health. Prescribing valproate for bipolar disorder. Topic 15a baseline audit report. Royal College of Psychiatrists; 2016."},{"issue":"1","key":"3322_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1192\/bjp.2018.257","volume":"214","author":"D Hidalgo-Mazzei","year":"2019","unstructured":"Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. Br J Psychiatry J Ment Sci. 2019;214(1):27\u201335. https:\/\/doi.org\/10.1192\/bjp.2018.257.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"3","key":"3322_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1017\/S0924270800035547","volume":"12","author":"DJ Kupfer","year":"2000","unstructured":"Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA, et al. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr. 2000;12(3):110\u20134. https:\/\/doi.org\/10.1017\/S0924270800035547.","journal-title":"Acta Neuropsychiatr"},{"key":"3322_CR11","volume-title":"Paying the price : the cost of mental health care in England to 2026","author":"P McCrone","year":"2008","unstructured":"McCrone P. Paying the price : the cost of mental health care in England to 2026. London: The King\u2019s Fund; 2008."},{"issue":"3","key":"3322_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jad.2011.06.016","volume":"133","author":"AH Young","year":"2011","unstructured":"Young AH, Rigney U, Shaw S, Emmas C, Thompson JM. Annual cost of managing bipolar disorder to the UK healthcare system. J Affect Disord. 2011;133(3):450\u20136. https:\/\/doi.org\/10.1016\/j.jad.2011.06.016.","journal-title":"J Affect Disord"},{"key":"3322_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/BF02245568","volume":"115","author":"P Willner","year":"1994","unstructured":"Willner P, Lappas S, Cheeta S, Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl). 1994;115:454\u201362.","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"3322_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00210-009-0405-0","volume":"380","author":"K Kitagawa","year":"2009","unstructured":"Kitagawa K, Kitamura Y, Miyazaki T, Miyaoka J, Kawasaki H, Asanuma M, et al. Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats. Naunyn Schmiedeberg's Arch Pharmacol. 2009;380(1):59\u201366. https:\/\/doi.org\/10.1007\/s00210-009-0405-0.","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"3322_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2015.03.020","volume":"95","author":"W-H Chiu","year":"2015","unstructured":"Chiu W-H, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, et al. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson\u2019s disease. Neuropharmacology. 2015;95:367\u201376. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.03.020.","journal-title":"Neuropharmacology."},{"issue":"1-3","key":"3322_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2009.06.029","volume":"616","author":"ME Breuer","year":"2009","unstructured":"Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, et al. Antidepressant effects of pramipexole, a dopamine D3\/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats. Eur J Pharmacol. 2009;616(1-3):134\u201340. https:\/\/doi.org\/10.1016\/j.ejphar.2009.06.029.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"3322_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0893-133X(01)00358-X","volume":"25","author":"RS Duman","year":"2001","unstructured":"Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2001;25(6):836\u201344. https:\/\/doi.org\/10.1016\/S0893-133X(01)00358-X.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"issue":"10","key":"3322_CR18","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.2174\/1871527313666141130223723","volume":"13","author":"G Serafini","year":"2014","unstructured":"Serafini G, Hayley S, Pompili M, Dwivedi Y, Brahmachari G, Girardi P, et al. Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets? CNS Neurol Disord Drug Targets. 2014;13(10):1708\u201321. https:\/\/doi.org\/10.2174\/1871527313666141130223723.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"6","key":"3322_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/ene.13303","volume":"24","author":"T Shen","year":"2017","unstructured":"Shen T, Ye R, Zhang B. Efficacy and safety of pramipexole extended-release in Parkinson\u2019s disease: a review based on meta-analysis of randomized controlled trials. Eur J Neurol. 2017;24(6):835\u201343. https:\/\/doi.org\/10.1111\/ene.13303.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3322_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","volume":"31","author":"AFG Leentjens","year":"2009","unstructured":"Leentjens AFG, Koester J, Fruh B, Shephard DTS, Barone P, Houben JJG. The effect of pramipexole on mood and motivational symptoms in Parkinson\u2019s disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89\u201398. https:\/\/doi.org\/10.1016\/j.clinthera.2009.01.012.","journal-title":"Clin Ther"},{"issue":"6","key":"3322_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(10)70106-X.","journal-title":"Lancet Neurol"},{"issue":"5","key":"3322_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mp.2017.16","volume":"22","author":"AH Ashok","year":"2017","unstructured":"Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666\u201379. https:\/\/doi.org\/10.1038\/mp.2017.16.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"3322_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/10401230009147102","volume":"12","author":"J Sporn","year":"2000","unstructured":"Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 2000;12(3):137\u201340. https:\/\/doi.org\/10.3109\/10401230009147102.","journal-title":"Ann Clin Psychiatry Off J Am Acad Clin Psychiatr"},{"issue":"2","key":"3322_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1176\/appi.ajp.2015.15060788","volume":"173","author":"J Fawcett","year":"2016","unstructured":"Fawcett J, Rush AJ, Vukelich J, Diaz SH, Dunklee L, Romo P, et al. Clinical experience with high-dosage Pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. Am J Psychiatry. 2016;173(2):107\u201311. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15060788.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"3322_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-2001-15872","volume":"34","author":"G Perugi","year":"2001","unstructured":"Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34(4):137\u201341. https:\/\/doi.org\/10.1055\/s-2001-15872.","journal-title":"Pharmacopsychiatry."},{"issue":"5","key":"3322_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","volume":"4","author":"L Lattanzi","year":"2002","unstructured":"Lattanzi L, Dell\u2019Osso L, Cassano P, Pini S, Rucci P, Houck PR, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4(5):307\u201314. https:\/\/doi.org\/10.1034\/j.1399-5618.2002.01171.x.","journal-title":"Bipolar Disord"},{"issue":"3","key":"3322_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11126-010-9130-6","volume":"81","author":"RS El-Mallakh","year":"2010","unstructured":"El-Mallakh RS, Penagaluri P, Kantamneni A, Gao Y, Roberts RJ. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010;81(3):207\u201313. https:\/\/doi.org\/10.1007\/s11126-010-9130-6.","journal-title":"Psychiatr Q"},{"key":"3322_CR28","doi-asserted-by":"publisher","first-page":"372474","DOI":"10.1100\/2012\/372474","volume":"2012","author":"H Hori","year":"2012","unstructured":"Hori H, Kunugi H. The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial. ScientificWorldJournal. 2012;2012:372474.","journal-title":"ScientificWorldJournal."},{"issue":"1","key":"3322_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jad.2012.11.030","volume":"150","author":"B Dell\u2019osso","year":"2013","unstructured":"Dell\u2019osso B, Timtim S, Hooshmand F, Miller S, Wang PW, Hill SJ, et al. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. J Affect Disord. 2013;150(1):130\u20135. https:\/\/doi.org\/10.1016\/j.jad.2012.11.030.","journal-title":"J Affect Disord"},{"issue":"3","key":"3322_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","volume":"161","author":"JF Goldberg","year":"2004","unstructured":"Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564\u20136. https:\/\/doi.org\/10.1176\/appi.ajp.161.3.564.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"3322_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","volume":"56","author":"CA Zarate","year":"2004","unstructured":"Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54\u201360. https:\/\/doi.org\/10.1016\/j.biopsych.2004.03.013.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"3322_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2215-0366(15)00450-2","volume":"3","author":"JR Geddes","year":"2016","unstructured":"Geddes JR, Gardiner A, Rendell J, Voysey M, Tunbridge E, Hinds C, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2\u2008\u00d7\u20082 factorial randomised trial. Lancet Psychiatry. 2016;3(1):31\u20139. https:\/\/doi.org\/10.1016\/S2215-0366(15)00450-2.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"3322_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u201383. https:\/\/doi.org\/10.1016\/S0006-3223(02)01866-8.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"3322_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","volume":"42","author":"EG Altman","year":"1997","unstructured":"Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Biol Psychiatry. 1997;42(10):948\u201355. https:\/\/doi.org\/10.1016\/S0006-3223(96)00548-3.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"3322_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JBW, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137. https:\/\/doi.org\/10.1001\/archinte.166.10.1092.","journal-title":"Arch Intern Med"},{"issue":"4","key":"3322_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134(4):382\u20139. https:\/\/doi.org\/10.1192\/bjp.134.4.382.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"5","key":"3322_CR37","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci. 1978;133(5):429\u201335. https:\/\/doi.org\/10.1192\/bjp.133.5.429.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"1","key":"3322_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale. Br J Psychiatry J Ment Sci. 1995;167(1):99\u2013103. https:\/\/doi.org\/10.1192\/bjp.167.1.99.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"5","key":"3322_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1192\/bjp.180.5.461","volume":"180","author":"JC Mundt","year":"2002","unstructured":"Mundt JC, Marks IM, Shear MK, Greist JH. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry J Ment Sci. 2002;180(5):461\u20134. https:\/\/doi.org\/10.1192\/bjp.180.5.461.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"2","key":"3322_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.24023","volume":"27","author":"D Weintraub","year":"2012","unstructured":"Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease-rating scale. Mov Disord Off J Mov Disord Soc. 2012;27(2):242\u20137. https:\/\/doi.org\/10.1002\/mds.24023.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"1","key":"3322_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2(1):12. https:\/\/doi.org\/10.1186\/1477-7525-2-12.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"3322_CR42","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"1","key":"3322_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12888-017-1211-8","volume":"17","author":"PM Mitchell","year":"2017","unstructured":"Mitchell PM, Al-Janabi H, Byford S, Kuyken W, Richardson J, Iezzi A, et al. Assessing the validity of the ICECAP-A capability measure for adults with depression. BMC Psychiatry. 2017;17(1):46. https:\/\/doi.org\/10.1186\/s12888-017-1211-8.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"3322_CR44","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12955-017-0825-3","volume":"15","author":"F Vergunst","year":"2017","unstructured":"Vergunst F, Jenkinson C, Burns T, Anand P, Gray A, Rugk\u00e5sa J, et al. Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH). Health Qual Life Outcomes. 2017;15(1):250. https:\/\/doi.org\/10.1186\/s12955-017-0825-3.","journal-title":"Health Qual Life Outcomes"},{"key":"3322_CR45","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.4559790","volume-title":"HEQ (Health Economics Questionnaire) Version v5.0 (08\u201309-2016)","author":"J Simon","year":"2016","unstructured":"Simon J, Mayer S. HEQ (Health Economics Questionnaire) Version v5.0 (08\u201309-2016); 2016. https:\/\/doi.org\/10.5281\/zenodo.4559790."},{"key":"3322_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(09)61828-6","volume":"375","author":"JR Geddes","year":"2010","unstructured":"BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin J-M, Cipriani A, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet Lond Engl. 2010;375:385\u201395.","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"3322_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"GM Goodwin","year":"2016","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol Oxf Engl. 2016;30(6):495\u2013553. https:\/\/doi.org\/10.1177\/0269881116636545.","journal-title":"J Psychopharmacol Oxf Engl."},{"key":"3322_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nicl.2016.06.007","volume":"12","author":"A Deutschl\u00e4nder","year":"2016","unstructured":"Deutschl\u00e4nder A, la Foug\u00e8re C, Boetzel K, Albert NL, Gildehaus F-J, Bartenstein P, et al. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2\/3 receptors in Parkinson\u2019s disease patients. NeuroImage Clin. 2016;12:41\u20136. https:\/\/doi.org\/10.1016\/j.nicl.2016.06.007.","journal-title":"NeuroImage Clin"},{"key":"3322_CR49","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbr.2014.07.055","volume":"274","author":"R Moraga-Amaro","year":"2014","unstructured":"Moraga-Amaro R, Gonzalez H, Pacheco R, Stehberg J. Dopamine receptor D3 deficiency results in chronic depression and anxiety. Behav Brain Res. 2014;274:186\u201393. https:\/\/doi.org\/10.1016\/j.bbr.2014.07.055.","journal-title":"Behav Brain Res"},{"key":"3322_CR50","doi-asserted-by":"publisher","first-page":"107597","DOI":"10.1016\/j.neuropharm.2019.04.003","volume":"158","author":"CJ Jordan","year":"2019","unstructured":"Jordan CJ, Humburg B, Rice M, Bi G-H, You Z-B, Shaik AB, et al. The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology. 2019;158:107597. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.003.","journal-title":"Neuropharmacology"},{"issue":"10","key":"3322_CR51","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.biopsych.2020.02.017","volume":"88","author":"SM Groman","year":"2020","unstructured":"Groman SM, Hillmer AT, Liu H, Fowles K, Holden D, Morris ED, et al. Midbrain D3 receptor availability predicts escalation in cocaine self-administration. Biol Psychiatry. 2020;88(10):767\u201376. https:\/\/doi.org\/10.1016\/j.biopsych.2020.02.017.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"3322_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0269881118756059","volume":"32","author":"F Caravaggio","year":"2018","unstructured":"Caravaggio F, Fervaha G, Browne CJ, Gerretsen P, Remington G, Graff-Guerrero A. Reward motivation in humans and its relationship to dopamine D2\/3 receptor availability: a pilot study with dual [11C]-raclopride and [11C]-(+)-PHNO imaging. J Psychopharmacol Oxf Engl. 2018;32(3):357\u201366. https:\/\/doi.org\/10.1177\/0269881118756059.","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"5","key":"3322_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/ijnp\/pyy005","volume":"21","author":"J Wang","year":"2018","unstructured":"Wang J, Jia Y, Li G, Wang B, Zhou T, Zhu L, et al. The dopamine receptor D3 regulates lipopolysaccharide-induced depressive-like behavior in mice. Int J Neuropsychopharmacol. 2018;21(5):448\u201360. https:\/\/doi.org\/10.1093\/ijnp\/pyy005.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3322_CR54","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). Arlington: American Psychiatric Association; 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596."},{"issue":"Suppl 20","key":"3322_CR55","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333 quiz 34\u201357.","journal-title":"J Clin Psychiatry"},{"key":"3322_CR56","volume-title":"Unit costs of health and social care 2017","author":"L Curtis","year":"2017","unstructured":"Curtis L, Burns A. Unit costs of health and social care 2017. Canterbury: University of Kent; 2017."},{"key":"3322_CR57","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2018","unstructured":"Joint Formulary Committee. British National Formulary. 76th ed. London: BMJ Group and Pharmaceutical Press; 2018.","edition":"76"},{"issue":"1","key":"3322_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","volume":"77","author":"R Tarricone","year":"2006","unstructured":"Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy Amst Neth. 2006;77(1):51\u201363. https:\/\/doi.org\/10.1016\/j.healthpol.2005.07.016.","journal-title":"Health Policy Amst Neth."},{"key":"3322_CR59","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"1997","unstructured":"Drummond M, O\u2019Brien B, Stoddard G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.","edition":"2"},{"key":"3322_CR60","volume-title":"Developing NICE guidelines: the manual 2014 (April 2017 update) - incorporating economic evaluation. National Institute for Health and Clinical Excellence","author":"NICE","year":"2017","unstructured":"NICE. Developing NICE guidelines: the manual 2014 (April 2017 update) - incorporating economic evaluation. National Institute for Health and Clinical Excellence; 2017."},{"key":"3322_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy Amst Neth. 1990;16:199\u2013208.","journal-title":"Health Policy Amst Neth"},{"key":"3322_CR62","volume-title":"Guideline for economic evaluations in healthcare","author":"Z Nederland","year":"2016","unstructured":"Nederland Z. Guideline for economic evaluations in healthcare. 2016. https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare."},{"issue":"3","key":"3322_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hec.3014","volume":"24","author":"TN Flynn","year":"2015","unstructured":"Flynn TN, Huynh E, Peters TJ, Al-Janabi H, Clemens S, Moody A, et al. Scoring the Icecap-a capability instrument. Estimation of a UK general population tariff. Health Econ. 2015;24(3):258\u201369. https:\/\/doi.org\/10.1002\/hec.3014.","journal-title":"Health Econ"},{"key":"3322_CR64","doi-asserted-by":"publisher","DOI":"10.1201\/9780429246593","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1994","unstructured":"Efron B, Tibshirani R. An introduction to the bootstrap. New York: CRC press; 1994."},{"issue":"2","key":"3322_CR65","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1192\/bjp.187.2.106","volume":"187","author":"E Fenwick","year":"2005","unstructured":"Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry J Ment Sci. 2005;187(2):106\u20138. https:\/\/doi.org\/10.1192\/bjp.187.2.106.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"2 Suppl","key":"3322_CR66","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","volume":"18","author":"AA Stinnett","year":"1998","unstructured":"Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak Int J Soc Med Decis Mak. 1998;18(2 Suppl):S68\u201380. https:\/\/doi.org\/10.1177\/0272989X98018002S09.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"3322_CR67","unstructured":"Northern Centre for Mood Disorders. 2019. Available from: http:\/\/www.mood-disorders.co.uk\/. Accessed 22 May 2021."},{"key":"3322_CR68","unstructured":"PAX-BD study. 2021. Available from: https:\/\/paxbd.org\/. Accessed 22 May 2021."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03322-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T09:07:24Z","timestamp":1625476044000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03322-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03322-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial is conducted in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2004 and in accordance with the principles of the Declaration of Helsinki. A Clinical Trial Authorisation from the MHRA (Eudract Ref: 2018\u2013002869-18). Approval from the Health Research Authority and a favourable opinion from the NHS Research Ethics Committee (REC: 19\/NE\/0233) was obtained prior to the start of the study. Investigators, RECs, trial participants and trial registries are notified of protocol amendments as appropriate.The study is run in accordance with the General Data Protection Regulation (May 2018) to safeguard the confidentiality of participants. The trial may be subject to audit by Sponsor representatives or inspection by the MHRA or NIHR HTA. Each investigator site will permit trial-related monitoring, audits and regulatory inspection including access to all essential and source data relating to the trial.Written informed consent is obtained from all participants prior to any study related activities. Staff and participants have the option of opting in or out of qualitative interviews, and participants have the right to withdraw from the study at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and study governance"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LA, GB, EC, LD, ND, TF, NG, SH, TH, PH, EMH, GM, PM, JM, JS, DS, JW, CW and FW have no competing interests.TC: Thomas Chadwick reports grants from NIHR (HTA) during the conduct of the study and outside the submitted work.PC: In last 5\u2009years, Paul Courtney has received speaker fees from Lundbeck. Paul Courtney is a shareholder in GlaxoSmithKline.JRG: JRG in past 5\u2009years has received research funding from MRC, NIHR, Wellcome. JRG is Director of NIHR Oxford Health Biomedical Research Centre and an Emeritus NIHR senior investigator; the views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.RHMW: In the last 5\u2009years, R. Hamish McAllister-Williams has received fees from American Center for Psychiatry & Neurology United Arab Emirates, British Association for Psychopharmacology, European College of Neuropsychophamracology, International Society for Affective Disorders, Janssen-Cilag ltd, LivaNova, Lundbeck, My Tomorrows, OCM Comunicaziona s.n.c., Pfizer, Qatar International Mental Health Conference, Sunovion, Syntropharma, UK Medical Research Council and Wiley; grant support from NIHR Efficacy and Mechanism Evaluation Panel and HTA Panel; and non-financial support from COMPASS Pathways.RM: Richard Morriss is supported by Nottingham NIHR Biomedical Centre, NIHR MindTech Medical Technology and In Vitro Collaboration and NIHR Applied Research Collaboration East Midlands.PS: Paul Stokes reports grant funding from NIHR HTA, during the conduct of the study. Paul Stokes reports non-financial support from Janssen Research and Development LLC, personal fees from Frontiers in Psychiatry, personal fees from Allergan, grants from H Lundbeck, grants and non-financial support from Corcept Therapeutics, outside the submitted work.SW: Stuart Watson has received speaker fees from Lundbeck, the British Association of Psychopharmacology and NIHR grant support.AY: In the past five years Allan Young has given paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma and COMPASS. AY is Principal Investigator on ESKETINTRD3004: \u201cAn Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression\u201d, \u201cThe Effects of Psilocybin on Cognitive Function in Healthy Participants\u201d and \u201cThe Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}